BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 10418981)

  • 21. Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells.
    Levenson AS; Svoboda KM; Kwaan HC; Jordan VC
    Cancer Lett; 1998 Mar; 125(1-2):215-20. PubMed ID: 9566718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.
    Herman ME; Katzenellenbogen BS
    J Steroid Biochem Mol Biol; 1996 Oct; 59(2):121-34. PubMed ID: 9010327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphological changes induced by 6-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800.
    Sourla A; Luo S; Labrie C; Bélanger A; Labrie F
    Endocrinology; 1997 Dec; 138(12):5605-17. PubMed ID: 9389549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
    Labrie F; Li S; Labrie C; Lévesque C; Mérand Y
    Breast Cancer Res Treat; 1995 Mar; 33(3):237-44. PubMed ID: 7749151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
    Osborne CK; Hobbs K; Clark GM
    Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice.
    Luo S; Sourla A; Labrie C; Gauthier S; Merand Y; Belanger A; Labrie F
    Endocrinology; 1998 May; 139(5):2645-56. PubMed ID: 9564882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
    Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
    Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A potent specific pure antiestrogen with clinical potential.
    Wakeling AE; Dukes M; Bowler J
    Cancer Res; 1991 Aug; 51(15):3867-73. PubMed ID: 1855205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of low-density lipoprotein oxidation by the pure antiestrogens ICI 182780 and EM-652 (SCH 57068).
    Hermenegildo C; García-Martínez MC; Tarín JJ; Cano A
    Menopause; 2002; 9(6):430-5. PubMed ID: 12439102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
    Müller V; Jensen EV; Knabbe C
    Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer.
    Labrie F; Champagne P; Labrie C; Roy J; Laverdière J; Provencher L; Potvin M; Drolet Y; Pollak M; Panasci L; L'Espérance B; Dufresne J; Latreille J; Robert J; Samson B; Jolivet J; Yelle L; Cusan L; Diamond P; Candas B
    J Clin Oncol; 2004 Mar; 22(5):864-71. PubMed ID: 14990642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA; Lippman ME; Katzenellenbogen BS
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
    Jordan VC
    Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pure antiestrogens and breast cancer.
    Elkak AE; Mokbel K
    Curr Med Res Opin; 2001; 17(4):282-9. PubMed ID: 11922402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
    Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
    Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
    Sömjen D; Waisman A; Kaye AM
    J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):389-96. PubMed ID: 9010344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells.
    Gong Y; Ballejo G; Murphy LC; Murphy LJ
    Cancer Res; 1992 Apr; 52(7):1704-9. PubMed ID: 1551100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.